Szakal sylain

[Pharmdca @Pharmdca]

$HRTX nice steady recovery from low 1.

[HODOR @Maximus_Holla]

$HRTX

[TripTrap @TripTrapTrading]

$ARDX Wanted to post this again incase you did not see it last week...

[Ardelyx @ardelyx]

Press Release: Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) https://t.co/G6GxN1086V

[Joe @Gantosj]

$ARDX, first breakout of the stubborn $4.96 resistance line
Now $4.98 & I expect a quick move up, then retesting before the next leg-up into the gap

[TripTrap @TripTrapTrading]

$ARDX - 04/17/23 08:34.57 - Wedbush Maintains Outperform on Ardelyx, Raises Price Target to $7.
Wedbush analyst Laura Chico maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $6 to $7. 🔥🚀

[TripTrap @TripTrapTrading]

$ARDX Weekly. The continued long slow upward grind of ARDX price action tells us that we still have a long way to go up... and NO I am NOT scared of any possible future offerings as I trust Raab and team to do the right thing.

[Ardelyx @ardelyx]

Press Release: Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings. https://t.co/VVAhNMw35k

[MASi @TOWiU2]

@crypto_biotech https://t.co/XaMv4KoQcQ
$ardx IBSRELA Prescriptions/Week
Week 55 = 31st of March

[MASi @TOWiU2]

@crypto_biotech https://t.co/TtjMsZACmL
$ardx IBSRELA Prescriptions/Week
Week 54 = 24th of March

[Frank @justfactstruth]

3/ $ARDX
conservative side. Given this we continue to view the tenapanor opportunity and **ARDX shares as under-appreciated and under-valued and think the stock can grind closer to our $15 target as investors begin to recognize tenapanor’s potential.

[Frank @justfactstruth]

2/ $ARDX
for 2023-2025, respectively. Plugging nephrologists’ peak tenapanor share projections (>50% in dialysis, 30% for CKD-ND) into our model verbatim implies $1B in upside to our 2025 US estimate, so we think our numbers are realistic and perhaps on the

[Frank @justfactstruth]

$ARDX This was highlight from old Piper note regarding tenapanor...
"Our estimates seem pretty conservative. As with all launches, the access/reimbursement picture will be the largest post approval issue and we continue to model US revenue of $292M, $619M and $782M

[Joe @Gantosj]

$ARDX is printing a New-52W-High with positive momentum, will test the next resistance line $4.96

Early Q2 is the IND resubmission
So, resubmission in April & if 2 months then FDA PDUFA in June!!

[RippinDT @danturner3000]

$ARDX continues to be the small gap mover of 2023 up 73% year to date

[zohm @zohmbastic]

$ARDX

[TripTrap @TripTrapTrading]

@Kachi_Galaxygod IMO…no!! $ARDX is turning into a monster with both the technicals and the fundamentals lining up… It has a long way to go $8 - $12 plus…

[TripTrap @TripTrapTrading]

$ARDX is in cruise control to fill the first big gap!!

[The Big Bull @J90666006]

$MULN Mullen automotive & Bollinger B1-Move to the production...big news coming soon...$muln own 60% of Bollinger 🚀🚀🚀🚀🚀